What are the investment strengths of Traws Pharma Inc (TRAW)?

Zero debt (0% D/E) preserves optionality for strategic partnerships or favorable financing terms if clinical data positive EV of 15.4M is cheap option on pipeline - intangibles of 2.6M suggest IP assets; any positive catalyst could 3-5x

What are the investment risks for Traws Pharma Inc (TRAW)?

Critical cash crisis: 6.4M cash vs -22M annual burn = forced dilution at depressed 22M market cap, 30-50% dilution likely Operating margin of -555% TTM with no path to profitability visible - pure binary bet on clinical outcomes

Traws Pharma Inc

TRAW

—

Build a strategy around TRAW

Traws Pharma Inc AI Insights

Informational only. Not investment advice.

As of 2025-12-10

Snapshot

Cash burn of -22.1M FCF TTM vs 6.4M cash on hand = ~3.5 months runway without dilution[Free Cash Flow TTM]
R&D of 9.0M TTM is 315% of revenue (2.8M) - pre-commercial biotech burning toward clinical milestones[Research and Development TTM]
Revenue grew 12% YoY and 133% 3Y CAGR but from tiny 2.8M base - scale irrelevant to valuation[Total Revenue 1Y Growth TTM]

Watch Triggers

Cash and Equivalents: Falls below 3M or financing announced — Sub-3M triggers immediate survival mode; financing terms reveal market's view of pipeline
Research and Development TTM: Drops >30% QoQ — R&D cuts signal pipeline deprioritization or cash preservation desperation
Shares Outstanding: Increases >20% — Dilution magnitude determines whether equity holders get wiped out or survive

Bull Case

Zero debt (0% D/E) preserves optionality for strategic partnerships or favorable financing terms if clinical data positive

Debt to EquityEnterprise Value

EV of 15.4M is cheap option on pipeline - intangibles of 2.6M suggest IP assets; any positive catalyst could 3-5x

Enterprise ValueGoodwill and Other Intangible Assets

Bear Case

Critical cash crisis: 6.4M cash vs -22M annual burn = forced dilution at depressed 22M market cap, 30-50% dilution likely

Cash and EquivalentsFree Cash Flow TTMMarket Cap TTM

Operating margin of -555% TTM with no path to profitability visible - pure binary bet on clinical outcomes

Operating Margin TTMNet Income TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

25%

Leverage TRAW's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Imminent dilution required - cash runway under 4 months at current burn rate

3-12mhigh

FCF burn of -22M TTM with only 6.4M cash
Zero debt capacity (equity only 4.5M)
Prior dilution pattern (116K stock issuance)

Cash dropped from 13.1M to 6.4M in TTMOperating cash flow -4.0M quarterly run rateNo debt on balance sheet to lever

Valuation Context

Caveats

Public Strategies Rankings

See how Traws Pharma Inc ranks across different investment strategies.

Leverage TRAW's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

TRAW Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$14.11M		—
Enterprise Value	$7.69M		—
P/E Ratio	0.00		—
Total Revenue - TTM	$2.85M	+1159.3%	—
Earnings Per Share (diluted) - TTM	$-1.82		—
Operating Margin - TTM	-555%	+10106.4%	—
Net Margin - TTM	-468%	+61826.6%	—
Free Cash Flow - TTM	$-22.05M		—
Return on Common Equity - TTM	0%		—
Beta 5Y (Monthly)	unknown		—

TRAW Dividend History

No dividends

TRAW Stock Splits

4 stock splits

09/23/2425:1 split

05/21/2115:1 split

09/26/1815:1 split

06/01/1610:1 split

TRAW SEC Filings

Filing Date	Report Date	Report Type	Filing Link
11/13/25	09/30/25	10-Q	0001104659-25-110845
08/14/25	06/30/25	10-Q	0001558370-25-011469
05/15/25	03/31/25	10-Q	0001558370-25-007872
03/31/25	12/31/24	10-K	0001558370-25-004165
11/14/24	09/30/24	10-Q	0001558370-24-015752
08/15/24	06/30/24	10-Q	0001558370-24-012279
05/15/24	03/31/24	10-Q	0001558370-24-008326
04/01/24	12/31/23	10-K	0001558370-24-004525
11/14/23	09/30/23	10-Q	0001558370-23-019049
08/14/23	06/30/23	10-Q	0001558370-23-014933
05/15/23	03/31/23	10-Q	0001558370-23-009964
03/30/23	12/31/22	10-K	0001558370-23-005107
11/14/22	09/30/22	10-Q	0001558370-22-017811
08/15/22	06/30/22	10-Q	0001558370-22-013675
05/13/22	03/31/22	10-Q	0001558370-22-008762
03/21/22	12/31/21	10-K	0001558370-22-004015
11/15/21	09/30/21	10-Q	0001558370-21-016043
08/16/21	06/30/21	10-Q	0001558370-21-011828
05/17/21	03/31/21	10-Q	0001104659-21-068301
03/18/21	12/31/20	10-K	0001104659-21-038452
11/16/20	09/30/20	10-Q	0001104659-20-125819
08/12/20	06/30/20	10-Q	0001104659-20-093990
05/15/20	03/31/20	10-Q	0001104659-20-062608
03/27/20	12/31/19	10-K	0001047469-20-001878
11/12/19	09/30/19	10-Q	0001104659-19-062715
08/14/19	06/30/19	10-Q	0001104659-19-045963
05/15/19	03/31/19	10-Q	0001104659-19-029745
04/01/19	12/31/18	10-K	0001047469-19-001839
11/14/18	09/30/18	10-Q	0001104659-18-068490
08/14/18	06/30/18	10-Q	0001104659-18-052015
05/15/18	03/31/18	10-Q	0001104659-18-033471
03/16/18	12/31/17	10-K	0001047469-18-001777
11/09/17	09/30/17	10-Q	0001104659-17-067204
08/14/17	06/30/17	10-Q	0001104659-17-051848
05/15/17	03/31/17	10-Q	0001104659-17-032824
03/29/17	12/31/16	10-K	0001047469-17-002146
11/14/16	09/30/16	10-Q	0001104659-16-156981
08/15/16	06/30/16	10-Q	0001104659-16-139775
05/11/16	03/31/16	10-Q	0001104659-16-120107
03/28/16	12/31/15	10-K	0001047469-16-011628
11/12/15	09/30/15	10-Q	0001104659-15-078285
08/13/15	06/30/15	10-Q	0001104659-15-059318
05/15/15	03/31/15	10-Q	0001104659-15-038689
03/30/15	12/31/14	10-K	0001047469-15-002952
11/14/14	09/30/14	10-Q	0001104659-14-080975
08/14/14	06/30/14	10-Q	0001104659-14-061083
05/15/14	03/31/14	10-Q	0001104659-14-039343
03/20/14	12/31/13	10-K	0001047469-14-002718
11/14/13	09/30/13	10-Q	0001104659-13-084775
09/06/13	06/30/13	10-Q	0001104659-13-068496
07/25/13	03/31/13	424B4	0001047469-13-007768
07/25/13	12/31/12	424B4	0001047469-13-007768
11/14/13	09/30/12	10-Q	0001104659-13-084775
09/06/13	06/30/12	10-Q	0001104659-13-068496
07/25/13	03/31/12	424B4	0001047469-13-007768